Affiliation:
1. The Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark Kogens Lyngby DK‐2800 Denmark
2. Systems and Synthetic Biology Division Department of Life Sciences Chalmers University of Technology Gothenburg SE‐412 96 Sweden
3. Department of Food Science and Biotechnology Sejong University Gwangjin‐Gu Seoul 05006 Republic of Korea
4. Division of Biomedical Sciences School of Medicine University of California Riverside CA 92521 USA
5. Faculty of Engineering Science KU Leuven Leuven 3000 Belgium
Abstract
AbstractCancer remains one of the most challenging health issues globally, demanding innovative therapeutic approaches for effective treatment. Nanoparticles, particularly those composed of gold, silver, and iron oxide, have emerged as promising candidates for changing cancer therapy. This comprehensive review demonstrates the landscape of nanoparticle‐based oncological interventions, focusing on the remarkable advancements and therapeutic potentials of gold, silver, and iron oxide nanoparticles. Gold nanoparticles have garnered significant attention for their exceptional biocompatibility, tunable surface chemistry, and distinctive optical properties, rendering them ideal candidates for various cancer diagnostic and therapeutic strategies. Silver nanoparticles, renowned for their antimicrobial properties, exhibit remarkable potential in cancer therapy through multiple mechanisms, including apoptosis induction, angiogenesis inhibition, and drug delivery enhancement. With their magnetic properties and biocompatibility, iron oxide nanoparticles offer unique cancer diagnosis and targeted therapy opportunities. This review critically examines the recent advancements in the synthesis, functionalization, and biomedical applications of these nanoparticles in cancer therapy. Moreover, the challenges are discussed, including toxicity concerns, immunogenicity, and translational barriers, and ongoing efforts to overcome these hurdles are highlighted. Finally, insights into the future directions of nanoparticle‐based cancer therapy and regulatory considerations, are provided aiming to accelerate the translation of these promising technologies from bench to bedside.
Funder
NordForsk
Danmarks Frie Forskningsfond
Novo Nordisk Pharma
Lundbeck Foundation
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献